Vaccine Adjuvants Market by Product (Adjuvant Emulsions, Combination Adjuvants, Mineral Adjuvants), Route of Administration (Intradermal, Intramuscular, Intranasal), Disease, Application - Global Forecast 2024-2030


Attention: There is an updated edition available for this report.

Vaccine Adjuvants Market by Product (Adjuvant Emulsions, Combination Adjuvants, Mineral Adjuvants), Route of Administration (Intradermal, Intramuscular, Intranasal), Disease, Application - Global Forecast 2024-2030


The Vaccine Adjuvants Market size was estimated at USD 825.65 million in 2023 and expected to reach USD 884.18 million in 2024, at a CAGR 7.88% to reach USD 1,404.20 million by 2030.

Global Vaccine Adjuvants Market

Vaccine adjuvants are essential components in the formulation of vaccines, which enhance and modulate the immune response elicited by the antigen present in the vaccine. The vaccine adjuvants encompass various products, including aluminum salts, oil emulsions, saponins, cytokines, and toll-like receptor agonists. The vaccine adjuvants have diverse applications, such as infectious diseases, cancer immunotherapy, allergy treatment, autoimmune disorders management, and veterinary medicine. Growth factors driving the market include growing demand for effective vaccines due to heightened public awareness about preventive healthcare measures, rising investments from governments and private entities for research & development activities, and favorable reimbursement policies in developed markets. Additionally, novel vaccination technologies such as mRNA-based approaches are anticipated to boost demand for effective adjuvants. Partnering with academic institutes or smaller biotechnology companies for novel adjuvant research and introduction of innovative adjuvants targeting specific immune mechanisms and addressing unmet clinical needs offers substantial prospects for the vaccine adjuvant market. However, the market faces limitations such as stringent regulatory processes, high development & manufacturing costs, potential safety concerns associated with specific adjuvants, and patent expirations leading to increased competition and reduced profit margins. The challenges in optimizing adjuvant combinations for efficacy and safety may impede adoption rates.

Regional Insights

The vaccine adjuvants market is evolving in the Americas with a high demand for innovative adjuvants to enhance immune responses. The U.S. government is investing heavily in research initiatives to support adjuvant discovery. The European Union represents substantial growth potential for vaccine adjuvants due to its well-established healthcare infrastructure and ongoing clinical trials. In the Middle East, several nations are actively boosting their immunization programs with assistance from government and non-governmental organizations. The African region's growth in vaccine adjuvants can be attributed to increased funding for immunization programs by international organizations, governments, and NGOs. The vaccine adjuvants market is growing in the APAC region owing to investments in advanced vaccine technologies. Besides, emphasis on the development of novel vaccine technologies is anticipated to boot the use of vaccine adjuvants across the end-use sectors globally.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Vaccine Adjuvants Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vaccine Adjuvants Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Vaccine Adjuvants Market, highlighting leading vendors and their innovative profiles. These include Agenus Inc., Aphios Corporation, Bioveta, A.S., Croda International PLC, CSL Limited, Dynavax Technologies Corporation, GlaxoSmithKline PLC, Hayashibara Co., Ltd. by NAGASE & CO., LTD., InvivoGen, Merck KGaA, Novavax, Inc., OZ Biosciences SAS, Pacific GeneTech Limited, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Vaccine Adjuvants Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Adjuvant Emulsions
Combination Adjuvants
Mineral Adjuvants
Particulate Adjuvants
Route of Administration
Intradermal
Intramuscular
Intranasal
Oral
Subcutaneous
Disease
Cancer
Infectious Diseases
Application
Human
Veterinary
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Vaccine Adjuvants Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vaccine Adjuvants Market?
3. What are the technology trends and regulatory frameworks in the Vaccine Adjuvants Market?
4. What is the market share of the leading vendors in the Vaccine Adjuvants Market?
5. Which modes and strategic moves are suitable for entering the Vaccine Adjuvants Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Vaccine Adjuvants Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidences of infectious and zoonotic diseases
5.1.1.2. Need to increase the effectiveness of vaccines
5.1.1.3. Growth in livestock operations and prevalence of associated diseases
5.1.2. Restraints
5.1.2.1. Incompatibility of mineral adjuvant with recombinant proteins and sub-unit vaccines
5.1.3. Opportunities
5.1.3.1. Rising potential of combination adjuvants
5.1.3.2. Increasing development of vaccines
5.1.4. Challenges
5.1.4.1. Capital-intensive and time-consuming development and approval process
5.2. Market Segmentation Analysis
5.2.1. Diseases: Burgeoning use of vaccine adjuvants to increase the efficacy of cancer vaccines
5.2.2. Product: Increasing preference for adjuvant emulsions for those with compromised immune systems
5.2.3. Application: Increasing use of vaccine adjuvants for human vaccines
5.2.4. Route of Administration: Proliferating use of vaccine adjuvants through intradermal administration
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Vaccine Adjuvants Market, by Product
6.1. Introduction
6.2. Adjuvant Emulsions
6.3. Combination Adjuvants
6.4. Mineral Adjuvants
6.5. Particulate Adjuvants
7. Vaccine Adjuvants Market, by Route of Administration
7.1. Introduction
7.2. Intradermal
7.3. Intramuscular
7.4. Intranasal
7.5. Oral
7.6. Subcutaneous
8. Vaccine Adjuvants Market, by Disease
8.1. Introduction
8.2. Cancer
8.3. Infectious Diseases
9. Vaccine Adjuvants Market, by Application
9.1. Introduction
9.2. Human
9.3. Veterinary
10. Americas Vaccine Adjuvants Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Vaccine Adjuvants Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Vaccine Adjuvants Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Agreement, Collaboration, & Partnership
13.3.1.1. Pritzker School of Molecular Engineering enters Academic-Industry partnership to create Next Generation vaccines
13.3.1.2. Croda Partners on Vaccine Adjuvants
13.3.2. New Product Launch & Enhancement
13.3.2.1. R21/Matrix-M Malaria Vaccine Developed By University Of Oxford Receives Regulatory Clearance For Use In Ghana
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Agenus Inc.
14.1.2. Aphios Corporation
14.1.3. Bioveta, A.S.
14.1.4. Croda International PLC
14.1.5. CSL Limited
14.1.6. Dynavax Technologies Corporation
14.1.7. GlaxoSmithKline PLC
14.1.8. Hayashibara Co., Ltd. by NAGASE & CO., LTD.
14.1.9. InvivoGen
14.1.10. Merck KGaA
14.1.11. Novavax, Inc.
14.1.12. OZ Biosciences SAS
14.1.13. Pacific GeneTech Limited
14.1.14. Takeda Pharmaceutical Company Limited
14.1.15. Thermo Fisher Scientific Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. VACCINE ADJUVANTS MARKET RESEARCH PROCESS
FIGURE 2. VACCINE ADJUVANTS MARKET SIZE, 2023 VS 2030
FIGURE 3. VACCINE ADJUVANTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. VACCINE ADJUVANTS MARKET DYNAMICS
FIGURE 7. VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
FIGURE 12. VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 14. VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. VACCINE ADJUVANTS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. VACCINE ADJUVANTS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings